Perspective of personalized treatment of immunoglobulin A-nephropathy

Authors

DOI:

https://doi.org/10.22141/2307-1257.9.1.2020.196910

Keywords:

immunoglobulin A-nephropathy, treatment, Oxford classification, risk factors, immunosuppression, review

Abstract

The search of personalized treatment for a subject with immunoglobulin A-nephropathy (IgAN) attracts attention of nephrologists all over the world. According to the Kidney Di­sease: Improving Global Outcomes guidelines, persistentprotei­nuria > 1 g/day for 3–6 months despite optimized supportive care is considered as indication to corticosteroid/immunosuppressive treatment in IgAN patients. The Oxford classification study and subsequent investigations have revealed the value of pathologic risk factors in disease progression regardless of proteinuria, blood pressure level and glomerular filtration rate at renal biopsy. Meanwhile, new studies have provided an improved understanding of the pathogenetic mechanisms leading to kidney tissue damage in IgAN. This review provides the possibility of using treatment based on pathological changes in the individual patient with IgAN, taking into consideration the pathogenetic mechanisms prevailing at the time of renal biopsy.

Downloads

Download data is not yet available.

References

Cattran DC, Feehally J, Terence Cook HT, et al. Kidney Disease: Improving Global Outcomes Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2012;2 (2):139–274. doi:10.1038/kisup.2012.9.

Rauen T, Eitner F, Fitzner C, et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373(23):2225–2236. doi:10.1056/NEJMoa1415463.

Lv J, Zhang H, Wong MG, et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2017;318(5):432–442. doi:10.1001/jama.2017.9362.

Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117–2127. doi:10.1016/S0140-6736(17)30550-0.

Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–556. doi:10.1038/ki.2009.168.

Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. J Am Soc Nephrol. 2015;26(9):2248–2258. doi:10.1681/ASN.2014070697.

Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1(3):511–517. doi:10.2215/CJN.01120905.

Kamei K, Nakanishi K, Ito S, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1301–1307. doi:10.2215/CJN.08630910.

Soares MF, Roberts IS. IgA nephropathy: an update. Curr Opin Nephrol Hypertens. 2017;26(3):165–171. doi:10.1097/MNH.0000000000000312.

Hou JH, Le WB, Chen N, et al. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. Am J Kidney Dis. 2017;69(6):788–795. doi:10.1053/j.ajkd.2016.11.027.

Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–836. doi:10.1038/ki.2014.63.

Bellur SS, Lepeytre F, Vorobyeva O, et al. Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int. 2017;91(1):235–243. doi:10.1016/j.kint.2016.09.029.

Coppo R, D'Arrigo G, Tripepi G, et al. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant. 2018;10.1093/ndt/gfy302. doi:10.1093/ndt/gfy302.

D'Amico G, Napodano P, Ferrario F, Rastaldi MP, Arrigo G. Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall. Kidney Int. 2001;59(2):682–692. doi:10.1046/j.1523-1755.2001.059002682.x.

Haas M, Verhave JC, Liu ZH, et al. A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. J Am Soc Nephrol. 2017;28(2):691–701. doi:10.1681/ASN.2016040433.

Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–1021. doi:10.1016/j.kint.2017.02.003.

Shen XH, Liang SS, Chen HM, et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol. 2015;28(4):441–449. doi:10.1007/s40620-014-0165-x.

Hou JH, Le WB, Chen N, et al. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. Am J Kidney Dis. 2017;69(6):788–795. doi:10.1053/j.ajkd.2016.11.027.

Kim SM, Moon KC, Oh KH, et al. Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome. J Korean Med Sci. 2009;24 Suppl(Suppl 1):S44–S49. doi:10.3346/jkms.2009.24.S1.S44.

Lai KN, Lai FM, Chan KW, Ho CP, Leung AC, Vallance-Owen J. An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am J Clin Pathol. 1986;86(6):716–723. doi:10.1093/ajcp/86.6.716.

Downloads

Published

2021-09-08

How to Cite

Komissarov, K. (2021). Perspective of personalized treatment of immunoglobulin A-nephropathy. KIDNEYS, 9(1), 4–9. https://doi.org/10.22141/2307-1257.9.1.2020.196910

Issue

Vol. 9 No. 1 (2020)

Section

Guest Articles

License

Copyright (c) 2020 K.S. Komissarov

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.